Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis

  • J Neuroimmunol. 2012 Oct 15;251(1-2):45-54. doi: 10.1016/j.jneuroim.2012.07.003.
Elias Toubi  1 ,  Shahar Nussbaum ,  Elsebeth Staun-Ram ,  Ayelet Snir ,  Doron Melamed ,  Liat Hayardeny ,  Ariel Miller
Affiliations
  • 1. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 31096 Haifa, Israel.
PMID: 22846497 DOI: 10.1016/j.jneuroim.2012.07.003
Abstract

Laquinimod is an orally administered drug under development for the treatment of Multiple Sclerosis (MS), lacking a fully elucidated mode of action. We assessed the immunomodulatory effects of laquinimod in vitro on human B cells from healthy or MS patients, cultured alone or with CD4(+) T cells. Laquinimod modulated B cell markers, mainly by increasing the regulatory ones CD25, IL10 and CD86, and decreased IL4, while increasing IL10 and TGFβ in both B and T cells, in a B cell-mediated manner. These findings shed additional light on the mechanisms underlying the effects of laquinimod in MS and potentially Other immune-mediated diseases.

Products